Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 3 Study of Leniolisib in Pediatric APDS Patients (4–11 Years) with Long-term Extension
2022-001624-14Phase 3Active
- Sponsor
- Pharming Group
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of leniolisib in Activated PI3Kδ syndrome (APDS), sponsored by Pharming Group. Primary endpoints: Safety (Part I), Pharmacokinetics (Part I) and 2 more. Started Jul 2022; status: active.
02
Drugs
leniolisib
03
Conditions
Activated PI3Kδ syndrome (APDS)
Beyond the preview
Go deeper on 2022-001624-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001624-14.